Atypical antipsychotics have very different adverse effect profiles and should not be lumped together [1]

Archives of Internal Medicine

Volumn 166, Issue 5, 2006, Pages 586-

  Friedman, Joseph H ^a  

^a Parkinson's Disease and Movement Disorders Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

AKATHISIA; CLINICAL TRIAL; DRUG LABELING; DYSTONIA; HUMAN; HYPERPROLACTINEMIA; LETTER; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; TARDIVE DYSKINESIA; COMPARATIVE STUDY; HEALTH STATUS; MENTAL DISEASE; NOTE; RISK FACTOR;

AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; HEALTH STATUS; HUMANS; MENTAL DISORDERS; RISK FACTORS;

EID: 33644981805     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.5.586-a     Document Type: Letter

References (5)

1. Rochon PA, Stukel TA, Sykora K, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882-1888.
2. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf. 2003;26:643-659.
3. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson sensitive populations. J Geriatr Psychiatry Neurol. 2002;15:156-170.
4. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychotic and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13:722-730.
5. Friedman JH, Fernandez HH, Trieschmann MM. Parkinsonism in a nursing home: underrecognition. J Geriatr Psychiatry Neurol. 2004;17:39-41.